18,958 results match your criteria Oncology[Journal]


Good outcomes for patients with classical Hodgkin lymphoma.

Authors:
Elizabeth Gourd

Lancet Oncol 2019 Feb 14. Epub 2019 Feb 14.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30069-5DOI Listing
February 2019

UK health tourism for private cancer care.

Authors:
Talha Khan Burki

Lancet Oncol 2019 Feb 14. Epub 2019 Feb 14.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30070-1DOI Listing
February 2019

Postoperative Treatment of Oropharyngeal Cancer in the Era of Human Papillomavirus.

Curr Treat Options Oncol 2019 Feb 15;20(3):20. Epub 2019 Feb 15.

Department of Head and Neck Oncologic Surgery, Head and Neck Institute, Cleveland Clinic, 9500 Euclid Avenue, A-71, Cleveland, OH, 44195, USA.

Opinion Statement: Despite an overall decline in the incidence of tobacco-related cancers, human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) of the oropharynx is on the rise. The prognosis of HPV-related oropharynx cancer (HPV-OPC) is generally favorable even in locoregionally advanced disease, and a variety of treatment options are available. Though the primary treatment modality of choice remains definitive radiation (RT), surgical resection followed by appropriate adjuvant therapy remains an option, especially in those patients who may not be favorable candidates for definitive radiotherapy, particularly when concurrent chemotherapy is warranted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0620-yDOI Listing
February 2019

Current Treatment Options for Breast Cancer Brain Metastases.

Curr Treat Options Oncol 2019 Feb 15;20(3):19. Epub 2019 Feb 15.

Department of Medicine, Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Ave, S73, Cleveland, OH, 44195, USA.

Opinion Statement: In the past, the standard of care for treatment of BM was whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), and surgery. There has been a greater role for medical therapies in the last two decades due to the discovery of driver mutations and corresponding targeted therapies. These innovations have dramatically altered the approach to treating these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0618-5DOI Listing
February 2019

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.

Lancet Oncol 2019 Feb 12. Epub 2019 Feb 12.

University College London Cancer Institute, London, UK.

Background: In the PROSPER trial, enzalutamide significantly improved metastasis-free survival in patients with non-metastatic, castration-resistant prostate cancer. Here, we report the results of patient-reported outcomes of this study.

Methods: In the randomised, double-blind, placebo-controlled, phase 3 PROSPER trial, done at 254 study sites worldwide, patients aged 18 years or older with non-metastatic, castration-resistant prostate cancer and a prostate-specific antigen doubling time of up to 10 months were randomly assigned (2:1) via an interactive voice web recognition system to receive oral enzalutamide (160 mg per day) or placebo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30898-2DOI Listing
February 2019

CHISELing a path forward in the treatment of early-stage non-small-cell lung cancer.

Lancet Oncol 2019 Feb 12. Epub 2019 Feb 12.

Division of Radiation Oncology, London Health Sciences Centre, London, ON N6A4L6, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30953-7DOI Listing
February 2019

Effective and well tolerated: where do these drugs fit now?

Lancet Oncol 2019 Feb 12. Epub 2019 Feb 12.

Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne 3000, VIC, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30901-XDOI Listing
February 2019

Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.

Lancet Oncol 2019 Feb 12. Epub 2019 Feb 12.

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.

Background: Stereotactic ablative body radiotherapy (SABR) is widely used to treat inoperable stage 1 non-small-cell lung cancer (NSCLC), despite the absence of prospective evidence that this type of treatment improves local control or prolongs overall survival compared with standard radiotherapy. We aimed to compare the two treatment techniques.

Methods: We did this multicentre, phase 3, randomised, controlled trial in 11 hospitals in Australia and three hospitals in New Zealand. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30896-9DOI Listing
February 2019

Improving the outcomes of checkpoint inhibitors in breast cancer.

Authors:
George E Peoples

Lancet Oncol 2019 Feb 11. Epub 2019 Feb 11.

Uniformed Services University of the Health Sciences, Bethesda, MD, USA; MD Anderson Cancer Center, Houston, TX, USA; Cancer Insight, San Antonio, TX 78208, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30068-3DOI Listing
February 2019

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

Lancet Oncol 2019 Feb 11. Epub 2019 Feb 11.

Institut Gustave Roussy, Université Paris Sud, INSERM U981, Villejuif, France.

Background: HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be mediated by immune mechanisms. We assessed the safety and anti-tumour activity of pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, added to trastuzumab in trastuzumab-resistant, advanced HER2-positive breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30812-XDOI Listing
February 2019

Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.

Oncology 2019 Feb 14:1-7. Epub 2019 Feb 14.

Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Purpose: Hand-foot skin reaction (HFSR) can deteriorate quality of life in patients receiving regorafenib. Cutaneous toxicity is a main adverse effect of multikinase inhibitors and has also been associated with clinical outcome. This study assessed the association between the antitumor efficacy of regorafenib and HFSR in patients with metastatic colorectal cancer (mCRC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495989DOI Listing
February 2019

Use of Immune Checkpoint Inhibitors in Mesothelioma.

Curr Treat Options Oncol 2019 Feb 14;20(2):18. Epub 2019 Feb 14.

Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd. Unit 432, Houston, TX, 77030, USA.

Opinion Statement: Recent advances in immunology have extended into the mesothelioma field. To date, only Japan has given regulatory approval to salvage nivolumab in chemo-refractory mesothelioma patients. The USA has included in the NCCN guidelines that pembrolizumab (in programmed death ligand 1 (PD-L1) immunohistochemistry (IHC)-positive patients) and nivolumab with or without ipilimumab (whatever the PD-L1 status is) are accepted salvage therapies. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0613-x
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0613-xDOI Listing
February 2019
2 Reads

Symptoms associated with risk of laryngeal cancer.

Authors:
Talha Khan Burki

Lancet Oncol 2019 Feb 7. Epub 2019 Feb 7.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30066-XDOI Listing
February 2019

Targeting tissue factor in advanced solid tumours.

Lancet Oncol 2019 Feb 7. Epub 2019 Feb 7.

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30912-4DOI Listing
February 2019

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.

Lancet Oncol 2019 Feb 7. Epub 2019 Feb 7.

Department of Oncology, Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark.

Background: Tisotumab vedotin is a first-in-human antibody-drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is associated with poor clinical outcomes. We aimed to establish the safety, tolerability, pharmacokinetic profile, and antitumour activity of tisotumab vedotin in a mixed population of patients with locally advanced or metastatic (or both) solid tumours known to express tissue factor.

Methods: InnovaTV 201 is a phase 1-2, open-label, dose-escalation and dose-expansion study done at 21 centres in the USA and Europe. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30859-3DOI Listing
February 2019
2 Reads

Female representation among US National Comprehensive Cancer Network guideline panel members.

Lancet Oncol 2019 Feb 7. Epub 2019 Feb 7.

Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30065-8DOI Listing
February 2019

E-cigarettes and smoking cessation.

Authors:
Manjulika Das

Lancet Oncol 2019 Feb 7. Epub 2019 Feb 7.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30067-1DOI Listing
February 2019

Updates on Minimally Invasive Surgery in Non-Small Cell Lung Cancer.

Authors:
Norihiko Ikeda

Curr Treat Options Oncol 2019 Feb 11;20(2):16. Epub 2019 Feb 11.

Department of Thoracic Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.

Opinion Statement: Video-assisted thoracic surgery (VATS) has become widely used since the 1990s and has become a standard treatment approach mainly for early-stage non-small cell lung cancer. The few randomized controlled trials providing evidence of the effectiveness of VATS lobectomy at present are supported by a large number of propensity-matched studies, several high-quality meta-analyses, and outcome studies. These studies provide comprehensive data demonstrating the lower morbidity, shorter chest tube duration, and shorter hospital stay of VATS than thoracotomy during the postoperative course. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0614-9DOI Listing
February 2019
1 Read

Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia.

Curr Treat Options Oncol 2019 Feb 11;20(2):15. Epub 2019 Feb 11.

Department of Pathology, University of Chicago, Chicago, IL, USA.

Opinion Statement: Acute myeloid leukemia (AML) patients with a complex karyotype (CK-AML) show at least 3 unrelated clonal cytogenetic abnormalities with notoriously poor outcome. Such cases fall into either AML with myelodysplasia-related changes or therapy-related AML in the current World Health Organization classification of AML. Allogeneic stem cell transplantation is one of the only treatment modalities that can provide a long-term survival benefit and is recommended as a consolidative treatment in patients who are able to achieve complete remission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0612-yDOI Listing
February 2019
1 Read

Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.

Curr Treat Options Oncol 2019 Feb 11;20(2):12. Epub 2019 Feb 11.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, DANA 1230, Boston, MA, 02215, USA.

Opinion Statement: Cisplatin has been established as an important agent in the neoadjuvant setting prior to radical cystectomy (RC) surgery for muscle-invasive urothelial cancer (MIUC) as well as in the unresectable or metastatic urothelial carcinoma (mUC) setting. Unfortunately, many patients in practice are felt to be "cisplatin-ineligible." Thus, it is vital that we develop treatment approaches and novel therapeutics for this population. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0609-6
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0609-6DOI Listing
February 2019
8 Reads

Innovating Cancer Care Delivery: the Example of the 4R Oncology Model for Colorectal Cancer Patients.

Curr Treat Options Oncol 2019 Feb 11;20(2):11. Epub 2019 Feb 11.

Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Opinion Statement: Care delivery innovation is necessary to address the growing complexity of cancer care across specialties and integrate new diagnostics, treatments, and services into care delivery. Informed by Cancer Care Delivery Research (CCDR), multilevel intervention research, and other disciplines, this article describes the 4-step cancer care delivery innovation cycle. The cycle guides collaborative efforts of cancer clinicians, researchers, patients, and other stakeholders to systematically define care delivery problems and formulate, test, and implement care innovations to effectively address problems. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0608-7DOI Listing
February 2019

Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.

Curr Treat Options Oncol 2019 Feb 11;20(2):14. Epub 2019 Feb 11.

Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Opinion Statement: Nonmetastatic castration-resistant prostate cancer (nmCRPC) comprises a relatively narrow niche of advanced prostate cancer, but the treatment landscape for men with nmCRPC has drastically changed over the past year. Prior to the SPARTAN and PROSPER trials, men with nmCRPC were commonly treated with first-generation androgen receptor antagonists, such as bicalutamide or flutamide, or with estrogens or ketoconazole, none of which were associated with any proven survival benefit. The SPARTAN trial evaluated apalutamide versus placebo for men with nmCRPC and found that apalutamide significantly improved metastasis-free survival (MFS), the primary endpoint of this trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0611-zDOI Listing
February 2019
1 Read

Palliative Cancer Care in the Outpatient Setting: Which Model Works Best?

Authors:
David Hui

Curr Treat Options Oncol 2019 Feb 11;20(2):17. Epub 2019 Feb 11.

Department of Palliative Care, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Unit 1414 - 1515 Holcombe Blvd., Houston, TX, 77030, USA.

Opinion Statement: Multiple randomized controlled trials have underscored the importance of timely referral to palliative care for patients with advanced cancer. Outpatient palliative care can facilitate timely referral and is increasingly available in many cancer centers. The key question is which model of outpatient palliative care is optimal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0615-8DOI Listing
February 2019
1 Read

Diagnosis and Management of Basal Cell Carcinoma.

Authors:
Keiji Tanese

Curr Treat Options Oncol 2019 Feb 11;20(2):13. Epub 2019 Feb 11.

Department of Dermatology, Keio University School of Medicine, Shinanomachi 35, Shinjuku, Tokyo, 160-8582, Japan.

Opinion Statement: Basal cell carcinomas (BCCs) are common skin cancers that tend to appear on sun-exposed skin. Pathobiologically, activation of the Hedgehog signaling pathway characterizes the majority of cases. In general, BCCs are slow-growing and rarely metastasize. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0610-0
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0610-0DOI Listing
February 2019
2 Reads

Guidelines for Treatment and Monitoring of Adult Survivors of Pediatric Brain Tumors.

Curr Treat Options Oncol 2019 Feb 9;20(1):10. Epub 2019 Feb 9.

Pediatric Endocrinology, Emory Children's Center/Emory Pediatric Institute, 2015 Uppergate Drive, Room 232, Atlanta, GA, 30322, USA.

Opinion Statement: Pathologies of pediatric brain tumors are more varied than those diagnosed in adults and survival outcomes more optimistic. Therapies for pediatric brain tumors are also diverse and treatment options are expanding. The growing number of adult survivors of childhood brain tumors is quite diverse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0602-0DOI Listing
February 2019

Combination therapies in prostate cancer: proceed with caution.

Authors:
Daniel E Spratt

Lancet Oncol 2019 Feb 6. Epub 2019 Feb 6.

Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109-0010, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30929-XDOI Listing
February 2019

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet Oncol 2019 Feb 6. Epub 2019 Feb 6.

University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Background: Abiraterone acetate plus prednisone or prednisolone improves progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer. Radium-223 improves overall survival and delays the onset of symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases. We assessed concurrent treatment with abiraterone acetate plus prednisone or prednisolone and radium-223 in such patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30860-XDOI Listing
February 2019
1 Read

Conservative management of adnexal masses.

Authors:
Taymaa May Amit Oza

Lancet Oncol 2019 Feb 5. Epub 2019 Feb 5.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Networks, Toronto, ON M5G 2M9, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30939-2DOI Listing
February 2019

Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study.

Lancet Oncol 2019 Feb 5. Epub 2019 Feb 5.

Department of Development and Regeneration, KU Leuven, Leuven, Belgium; Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium. Electronic address:

Background: Ovarian tumours are usually surgically removed because of the presumed risk of complications. Few large prospective studies on long-term follow-up of adnexal masses exist. We aimed to estimate the cumulative incidence of cyst complications and malignancy during the first 2 years of follow-up after adnexal masses have been classified as benign by use of ultrasonography. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183083
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30837-4DOI Listing
February 2019
2 Reads

Vitamin D and Omega-3 Supplements for Preventing Cancer and Other Chronic Diseases.

Authors:
JoAnn Manson

Oncology (Williston Park) 2019 01;33(1):36-8

View Article

Download full-text PDF

Source
January 2019

The Emerging Profile of Immunotherapy Approaches in the Treatment of AML.

Authors:
Naval Daver

Oncology (Williston Park) 2019 01;33(1):28-32

View Article

Download full-text PDF

Source
January 2019
1 Read

Management of Neutropenic Toxicity From CDK4/6 Inhibitors.

Oncology (Williston Park) 2019 01;33(1):26-7

View Article

Download full-text PDF

Source
January 2019

Current Strategies for the Management of Locoregional Breast Cancer Recurrence.

Oncology (Williston Park) 2019 01;33(1):19-25

Advances in the treatment of breast cancer have decreased the rate of isolated locoregional recurrences (ILRRs) over time. Surgery, radiation therapy, and systemic therapies are used to manage these failure events and their associated poor prognosis. Operable ipsilateral breast tumor recurrences (IBTRs) are treated by either salvage mastectomy or, in select cases, repeat lumpectomy. Read More

View Article

Download full-text PDF

Source
January 2019
2 Reads

Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial Cancer.

Oncology (Williston Park) 2019 01;33(1):11-8

Immune checkpoint inhibitors have revolutionized the field of oncology, providing a novel mechanism for anticancer therapy. Programmed death 1-targeting antibodies pembrolizumab and nivolumab and programmed death ligand 1 (PD-L1)-targeting antibodies atezolizumab, durvalumab, and avelumab have been approved for use in advanced urothelial cancer in the post-platinum setting or in the upfront setting in platinum-ineligible patients. While this represents a significant step forward in management of urothelial cancers, most patients do not have an objective response to these therapies. Read More

View Article

Download full-text PDF

Source
January 2019

Oncology Conference Highlights, Q4.

Oncology (Williston Park) 2019 01;33(1):8-10

View Article

Download full-text PDF

Source
January 2019

Key Advances in Oncology, 2018.

Oncology (Williston Park) 2019 01;33(1):6-8

View Article

Download full-text PDF

Source
January 2019

Tumor Treating Fields for Glioblastoma Treatment: Patient Satisfaction and Compliance With the Second-Generation Optune System.

Clin Med Insights Oncol 2019 29;13:1179554918825449. Epub 2019 Jan 29.

Novocure Ltd., Haifa, Israel.

Background: Tumor treating fields (TTFields) are a non-invasive antimitotic therapy that delivers alternating electric fields via the Optune system. The Phase III EF-14 trial in newly diagnosed glioblastoma multiforme (GBM) showed significantly improved progression-free, overall and long-term survival when Optune was used together with maintenance temozolomide (TMZ) compared with TMZ alone. Compliance (average monthly use) was associated with better clinical outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918825449DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351720PMC
January 2019

Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study.

Clin Med Insights Oncol 2019 30;13:1179554918825447. Epub 2019 Jan 30.

Medical Oncology Section, The Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Background: Regorafenib is a multi-kinase inhibitor approved for treatment of refractory advanced colorectal cancer. It was found in the clinical trials to have a modest benefit and significant toxicity. Our aim was to assess the outcome in our local clinic practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918825447DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354297PMC
January 2019

Pharmacologic management of cognitive impairment induced by cancer therapy.

Lancet Oncol 2019 Feb;20(2):e92-e102

Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA USA. Electronic address:

Cognitive dysfunction is a challenging adverse effect of chemotherapy and radiotherapy that has limited treatment options. Clinical trials for proposed pharmacotherapeutic interventions to help manage these cognitive symptoms have had conflicting results and no standard of care has yet been established. Pharmacotherapeutic approaches for cancer therapy-induced cognitive symptoms include CNS stimulants (eg, methylphenidate and modafinil), medications used in patients with memory impairment (eg, donepezil, memantine, and ginkgo biloba), and bone marrow supporting agents (eg, erythropoietin). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30938-0DOI Listing
February 2019
1 Read
24.690 Impact Factor

Cabozantinib-related pneumothorax in rapidly responding patients with renal cell carcinoma.

Lancet Oncol 2019 Feb;20(2):e124

Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), University of Verona, Verona, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30577-1DOI Listing
February 2019
1 Read

Challenges in anticancer drug R&D in China.

Lancet Oncol 2019 Feb;20(2):183-186

Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183086
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30865-9DOI Listing
February 2019
30 Reads

Betel nut chewing in high-income countries-lack of awareness and regulation.

Lancet Oncol 2019 Feb;20(2):181-183

Royal National Throat, Nose and Ear Hospital, University College London Hospitals NHS Trust, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30911-2DOI Listing
February 2019
2 Reads

Big influences on anti-obesity strategies.

Authors:

Lancet Oncol 2019 Feb;20(2):165

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30041-5DOI Listing
February 2019

Hepatotoxicities Induced by Neoadjuvant Chemotherapy in Colorectal Cancer Liver Metastases: Distinguishing the True From the False.

Clin Med Insights Oncol 2019 22;13:1179554918825450. Epub 2019 Jan 22.

Digestive Tumours Unit, Institut Bergonié, Bordeaux, France.

Background: Pre-operative chemotherapy for colorectal liver metastasis (CRLM) is thought to be the cause of hepatotoxicity of non-tumoural parenchyma. Studies on hepatotoxicity are contradictory. We investigated the impact of a single-line pre-operative chemotherapy on non-tumoural liver analysed by an expert hepatico-pancreatico-biliary pathologist, and the consequences on surgical outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918825450DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348554PMC
January 2019
1 Read

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.

Lancet Oncol 2019 Feb 1. Epub 2019 Feb 1.

Weill Cornell Medical College, NY, USA; New York Presbyterian Hospital, New York, NY, USA.

Background: VEGF and VEGF receptor 2 (VEGFR-2)-mediated signalling and angiogenesis can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess whether the addition of ramucirumab, a VEGFR-2 antagonist monoclonal antibody, to first-line chemotherapy improves outcomes in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.

Methods: For this double-blind, randomised, placebo-controlled, phase 3 trial done at 126 centres in 20 countries, we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate organ function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30791-5DOI Listing
February 2019
9 Reads
24.690 Impact Factor

No clear role for angiogenesis inhibitors in first-line therapy for stomach cancer.

Authors:
Annemieke Cats

Lancet Oncol 2019 Feb 1. Epub 2019 Feb 1.

Department of Gastrointestinal Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30892-1DOI Listing
February 2019

Blastic Plasmacytoid Dendritic Cell Neoplasm.

Curr Treat Options Oncol 2019 Feb 4;20(1). Epub 2019 Feb 4.

Department of Hematology and Medical Oncology, Moffitt Cancer Center/University of South Florida, 12902 USF Magnolia Dr, Tampa, FL, 33612, USA.

Opinion Statement: While there is a high initial response rate with standard chemotherapeutic regimens for blastic plasmacytoid dendritic cell neoplasm (BPDCN), the responses are typically not durable and this remains a very aggressive disease with generally poor outcomes. For this reason, the standard approach for eligible patients has been high-dose induction chemotherapy preferably with acute lymphoblastic leukemia (ALL)-based regimens followed by consolidation with allogeneic hematopoietic stem cell transplantation (alloHSCT). Unfortunately, many patients with this disease are elderly and/or frail and cannot tolerate this therapy, and the low-dose regimens being used in this population are generally not as effective. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0605-x
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0605-xDOI Listing
February 2019
3 Reads

Links between think tanks and the tobacco industry.

Authors:
Talha Khan Burki

Lancet Oncol 2019 Jan 31. Epub 2019 Jan 31.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30063-4DOI Listing
January 2019